Multiple sclerosis

  title={Multiple sclerosis},
  author={Ernst U. Walther and Reinhard Hohlfeld},
  pages={1622 - 1622}
Article abstract Interferon beta (IFNβ) reduces the relapse rate, disease activity as measured by serial MRI scanning, and disease progression of MS. Therapy with IFNβ may be associated with a number of adverse reactions. Relatively frequent side effects include flu-like symptoms, transient laboratory abnormalities, menstrual disorders, and increased spasticity. Dermal injection site reactions occur after subcutaneous application of IFNβ-1b and IFNβ-1a. Possible side effects of IFNβ include… 

Tables from this paper

Arthritis during interferon beta-1b treatment in multiple sclerosis

Clinical and laboratory findings of two MS patients who developed arthritis during IFN-β1b treatment, probably of autoimmune origin are presented.

Interferon-beta injection site reactions in patients with multiple sclerosis

Injection site reactions (ISRs), featured by erythema, edema, pain, and pruritus, are the most common adverse reactions and it is very important to adopt strategies to minimize ISRs by proper patient education and counseling.

The safety and efficacy of IFN-β products for the treatment of multiple sclerosis

Overall, IFN-β is safe and generally well tolerated, and reported adverse events were comparable between preparations, and systemic side effects can be effectively managed by dose escalation, use of an auto-injector and careful clinical monitoring.

Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis

There is growing evidence from clinical trials on relapsing-remitting MS and clinically isolated syndromes suggestive of MS that IFNβ-1b reduces the frequency and severity of relapses and the development of new and active brain lesions as assessed by magnetic resonance imaging.

Cutaneous Adverse Events Associated with Interferon-β Treatment of Multiple Sclerosis

A multiple sclerosis patient treated with interferon-β who developed new-onset psoriasis is presented and it is suggested that skin lesions may serve as biomarkers to allocate MS patients to adequate disease-modifying drugs.

Managing Risks with Immune Therapies in Multiple Sclerosis

This paper aims to provide an overview of currently available MS therapies, their modes of action and safety profiles, and the necessary therapy monitoring.

Thrombotic microangiopathy associated with use of interferon-beta

A patient who developed thrombotic microangiopathy during treatment with interferon-beta and improved after discontinuation and steroid therapy is reported.

Current Clinical Applications of Interferon

Flu-like symptoms, fever, headache, fatigue and myalgia are experienced by three quarters of patients, but this reaction can usually be managed with NSAIDs and resolved within the first three months after initiation of IFN--1b treatment.

Psoriasis during interferon beta treatment for multiple sclerosis

This case further supports that activation of psoriasis might be a rare side effect of IFNB therapy and suggests careful evaluation of concomitant morbidity to allow a patient-oriented treatment strategy.

Interferons in multiple sclerosis.

  • L. Kappos
  • Medicine, Biology
    Neurologic clinics
  • 2005



Side effect profile of interferon beta-lb in MS

If future clinical trials are to provide useful information on the value of interferon beta-1b in progressive MS, the side effects of fatigue and depression will need to be ameliorated to limit the drop-out rate from such trials.

Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon beta-1b.

Since some symptoms of thyroid dysfunction may be difficult to distinguish from typical MS-related symptoms, thyroid hormone levels should be checked when unexplained constitutional symptoms occur during IFN-beta-1b therapy.

Management of patients receiving interferon beta-1b for multiple sclerosis

Article abstract-Results of a double-blind, placebo-controlled study in ambulatory patients with relapsing-remitting MS showed that interferon beta-1b reduced the rate of exacerbations by one-third

Autoimmune events during interferon beta-1b treatment for multiple sclerosis

Clinical Toxicity of the Interferons

The mechanisms underlying toxic effects of the interferons are not well understood, and the incidence of adverse effects is usually dose- and duration-dependent.

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b

The annual exacerbation rates in NAB-negative patients receiving the 8-MIU dosage regimen are about 50% of those seen in untreated patients, a greater reduction than the one-third reduction earlier reported for the entire high-dose arm, and a meaningful treatment benefit.

Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis

Interferon beta‐ la had a significant beneficial impact in relapsing multiple sclerosis patients by reducing the accumulation of permanent physical disability, exacerbation frequency, and disease activity measured by gadolinium‐enhanced lesions on brain magnetic resonance images.

Anaphylactoid reaction to methyl prednisolone developing after starting treatment with interferon β-1b

  • D. Clear
  • Medicine
    Journal of neurology, neurosurgery, and psychiatry
  • 1999
The case of a 35 year old man with multiple sclerosis who became allergic to intravenous methyl prednisolone after the initiation of treatment with interferon β-1b is presented and what part the drug could have played in this is discussed.

Amelioration of flulike symptoms at the onset of interferon β‐ 1b therapy in multiple sclerosis by low‐dose oral steroids is related to a decrease in interleukin‐6 induction

The results support a relationship between IL‐6 induction and fever and suggest that side effects caused by steroid treatment can be ameliorated by steroids.